

10-06-05

FFW  
1642

EXPRESS MAIL No.: EV 400 858 695 US

Deposited: October 5, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service Express mail under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT, Commissioner for Patents, Washington, DC 20231

Customer No.

026418

/ Ruth Montalvo

Date: October 5, 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.

JG-EPC-5193/722489.00005

Examiner:

Fetterolf, Brandon J.

Application No.:

10/501,568

Group:

1642

Filed:

April 5, 2005

For:

CANCER TREATMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant herewith submits this Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98 and hereby makes of record the following references listed below :

U. S. PATENTPatent No.Publication DateName

4,924,012

May 8, 1990

Colin, Michel et al.

FOREIGN PATENTSPatent No.Publication DateName

WO 01/74905

October 11, 2001

Young, Robert James

WO 92/04380

March 19, 1992

Verhoeven, Martine

EP 0239 400

Sept. 9, 1987

Winter, Gregory Paul



## ARTICLES

ALVEREZ, et al., A Phase I, "Study of Combined Modality Intraperitoneal Radioimmunotherapy for Ovarian cancer, 2002, Clin. Cancer Res. 8 pp. 2806-2811

BAO Comparative Study on Subcutaneous, Intraperitoneal and Intrahepatic Transplantations in Nude Rat Bearing Hepatocellular Carcinoma, 1989, Zhonghua Zhong Liu Za Zhi, 11 pp. 245-247, China (Article in Chinese and English abstract enclosed)

BEHR et al., Improved Treatment of Medullary Thyroid Cancer in a Nude Mouse Model by Combined Radioimmunotherapy; Doxorubicin Potentiates the Therapeutic Efficacy of Radiolabeled antibodies in a Radioresistant Tumor Type, 1997, Cancer Res. 57, pp. 5309-5319.

BETTER, et al. Escherichia coli Secretion of an Active Chimeric Antibody Fragment, Science 240, pp. 1041-1043, 1988

ADIS Data Information, Iodine-131 Tositumomab, Biodrugs, pg. 17, 2003.

BIRD et al., Single-Chain Antigen-Binding Proteins, Science pgs. 422-427, 1988

BLUMENTHAL, "An In Vitro Model to Optimize Dose Scheduling Of Multimodal Radioimmunotherapy and Chemotherapy, Int. J. Cancer, pg. 108, 293-300, 2004

BURKE, "Combined Modality Radioimmunotherapy, Cancer, pgs 1320-1331, 2002

BURKE, "Cilgite Targeting of ... Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts, Cancer Research 62 pgs. 4263-4272, 2002

CARDILLO, et al., "Combined Gemcitabine and Radioimmunotherapy for the Treatment of Pancreatic Cancer, Int. J. Cancer; pgs. 386-392, 2002

CHALANDON et al., "Combined Radioimmunotherapy and Chemotherapy of Human Colon Carcinoma Grafts in Nude Mice, Advantages and Limitations," Anticancer Research, 12 pgs. 1131-1139, 1992

CHEUNG, et al., N7: "A Novel Multi-Modality Therapy of High Risk Neuroblastoma (NB) in Children Diagnosed Over 1 Year of Age, Medical and Pediatric Oncology," 36:227-230, 2001.

CLARKE et al., "Therapeutic Efficacy of Anti-Lewis Humanized 3S193 Radioimmunotherapy in a Breast Cancer Model: Enhanced Activity When Combined with Toxic Chemotherapy," Clinical Cancer Research, 6 pgs. 3621-3629, 2000

D'ANDREA et al., docetaxel and Paclitaxel in Breast Cancer Therapy: Present Status and Future Prospects, *Seminars in Oncology* 24 (4<sup>th</sup> Suppl. 13) pgs. 27-44, 1997

DENARDO et al., Synergistic Therapy of Breast Cancer with Y-90-Chimeric L6 and Paclitaxel in the Xenografted Mouse Model: Development of a Clinical Protocol, *Anticancer Res.* 18 pgs. 4011-4019, 1998

DENARDO et al., Synergistic of Toxol and Radioimmunotherapy with Yttrium-90-Labeled Chimeric L6 Antibody: Efficacy and Toxicity in Breast Cancer Xenografts, *Proc. Natl. Acad. Sci. USA* 94, 4000-4, 1997

DESRUES et al., Monoclonal Antibody Po66 Uptake By Human Lung Tumours Implanted in Nude Mice: Effect of Co-Administration with Doxorubicin, *Br. J. Cancer* 72 pgs., 1076-1082, 1995

DESRUES et al., "Treatment of Human Lung Carcinoma Xenografts with a Combination of 1311-Labelled Monoclonal Antibody Po66 and Doxorubicin, *Cancer Immunol Immunother*, 43, pgs. 269-74, 1996

FABRE et al., Docetaxel Antineoplastic Microtubule Stabilizer, *Drugs of the Future*, 20. pgs. 464-71, 1995.

GENDLER et al., "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas is made Up of Tandem Repeats," *J. of Biol. Chem.*, 263, pgs. 12820-23, 1986.

GILLIES, "Antibody Cytokine Concept Optimising the Therapeutic Potential of Antibody-Cytokine Fusion Proteins," London, June 27<sup>th</sup> and June 28<sup>th</sup> 2001.

GOLD et al., "Combined Yttrium-Dota-Labeled PAM4 "Antibody Radioimmunotherapy and Gemcitabine Radiosensitization for the Treatment of a Human Pancreatic Cancer Xenograft," *Int. J. Cancer* 109 pgs. 618-626, 2004.

GOLDENBERG, "The Role of Radiolabeled Antibodies in the Treatment of non-Hodgkin's Lymphoma: the Coming of Age of Radioimmunotherapy," *Critical Reviews in Oncology/Hematology*, 39 pgs. 195-201, 2001

GOPAL et al., "High-Dose chemo-Radioimmunotherapy with Autologous Stem Cell Support for Relapsed Mantle Cell Lymphoma," *Blood* vol. 99, pgs. 3158-3192, 2002

HERNANDEZ et al., "Radiobiology og Radioimmunotherapy: "Targeting CD20 B-Cell Antigen in non-Hodglin's Lymphoma," *Int. J. Radiation Oncology Biol. Phys.*, Vol. 59, pgs. 1274-1287, 2004

HUSTON et al., "Protein Engineering of Antibody Binding Sites: "Recovery of Specific Activity in an Anti-Digoxin Single-Chain F<sub>v</sub> analogue Produced in *Escherichia Coli*, *Proc. Natl. Acad. Sci. USA*, pgs. 5879-5883, 1988

JOHNSON et al., "Synergistic Cytotoxicity of Iodine – 131-Anti-CD20 Monoclonal Antibodies and Chemotherapy for Treatment of B-Cell Lymphomas", *Int. J. Cancer*, 85, 104-112, 2000

JONES et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse," *Nature*, Vol. 321, pgs 522-525, 1986

JUWEID, "Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical trials to Clinical Practice, *J. Nucl., Med.* 43 pgs. 1507-1529, 2002

KINUYA et al., "Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with Thalidomide in Human Cancer Xenografts", *Int. J. Cancer*, 43 pgs. 1084-1089, 2002

KINUYA et al., "Efficacy, Toxicity and Mode of Interaction of Combination Radioimmunotherapy with 5-fluorouracil in Colon Cancer Xenografts," *J. Cancer Res. Clin. Oncol*, 125 pgs. 630-636, 1999

KINUYA et al., "Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model," *JPN. J. Cancer Res.*, 43 pps. 1084-89, 2002

Seigo KINUYA et al., "Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model, *Jpn. J. Cancer Res.* 91, pps. 573-78, 2000

Seigo KINUYA et al., "Anti-Angiogenic Therapy and Radioimmunotherapy in Colon Cancer Xenografts, *Eur J. Nucl Med.*, vol. 28, No. 9, 28 pps 1306-12, 2001

Seigo KINUYA et al., "Improved Response of Colon Cancer Xenografts to Radioimmunotherapy with Pentoxifylline Treatment, *Eur. J. Nucl. Med.*, Vol. 28, pps. 750-755, 2001

Seigo KINUYA et al., "Improved Survival of Mice Bearing Liver Metastases of Colon Cancer Cells Treated with a Combination of Radioimmunotherapy and Antiangiogenic Therapy," *Euro J. Nucl. Med.* Vol. 31, pps. 981-85, 2004

Francoise KRAEBER-BODERE et al., "Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft, *Mol. Cancer Ther.* Vol. 1 pps. 267-74, 2002

Xiao LI et al., "Benefits of Combined Radioimmunotherapy and anti-angiogenic therapy in a Liver Metastasis Model of Human Colon Cancer Cells," *Eur. J. Nucl. Med. Mol. Imaging* Vol. 29 pps. 1669-1674, 2002.

Anthony MARAVEYAS et al., "Radiolabeled Antibody Combined with External Raditherapy for the Treatment of Head and Neck Cancer: Reconstruction of Theoretical Phantom of the Larynx for Radiation Dose Calculation to Local Tissues, *Cancer Research* 55 pps., 1020-1027, 1995

Ruby MEREDITH et al., "Intraperitoneal Radioimmunotherapy of Ovarian Cancer: A Phase I Study, *Cancer Biotherapy, Radiopharm* Vol. 16 pps, 305-15, 2001

Ivana MICALLEF, "Ongoing Trials with Yttrium 90-Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma, Clin Lymphoma 5, pps., S27-S32, 2004

Bruce NG et al., "Radiosensitization of Tumor-Targeted Radioimmunotherapy with Prolonged Toptecan Infusion in Human Breast Cancer Xenografts," Cancer Research 61, pps. 2996-3001, 2001

Robert O'DONNELL et al., "Combined Modality Radioimmunotherapy for Human Prostate Cancer Xenografts with Taxanes and Yttrium-DOTA-Peptide-ChL6, Prostate 50:27, pps. 27-37, 2002

R. Barbara PEDLEY et al., "Enhancement of Radioimmunotherapy by Drugs Modifying Tumour Blood Flow in a Colonic Xenograft Model, Int. J. Cancer 57 pps. 830-35, 1994

R. Barbara PEDLEY et al., "Ablation of Colorectal Xenografts with Combined Radioimmunotherapy and Tumor Blood Flow-Modifying Agents," Cancer Res. 56, pps. 3293-3300, 1996

R. Barbara PEDLEY et al., "Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastain A-4 3-O-Phosphate, Cancer Res. 61, pps. 4716-4722, 2001

R. Barbara PEDLEY et al., "Synergy Between Vascular Targeting Agents and Antibody-Directed Therapy, Int. J. Radiation Oncology Biol., Phys. 54 pps. 1524-31, 2002

Oliver PRESS, et al., "A Phase I/II Trial of Iodine-131-Tositumomab (anti-CD20), etoposide, cyclophosphamide, and Autologous Stem Cell Transplantation for Relapsed B-Cell Lymphomas, Am. Soc. Hematol., Blood, pps. Vol. 96, No. 9, 221-240, 2000

Oliver PRESS et al., "Immunotherapy of Non-Hodgkin's Lymphomas, Hematology, pps. 221-240, 2001

Oliver PRESS et al., "A Phase 2 Trial of CHOP Chemotherapy Followed by Tositumomab/iodine I 131 Tositumomab for Previously Untreated Follicular non-Hodgkin Lymphoma: Southwest Oncology Group Protocol S9911, Blood 102, 2003

M. REISER et al., "Current Treatment of Follicular non-Hodgkin's Lymphoma, Eur. J. Cancer 38 pps., 1167-1172, 2002

L. REICHMANN et al., "Reshaping Human Antibodies for Therapy," Nature 322, pps. 323-27, 1988

Jean Francois RIOU et al., "Effects of Toxotere on Murine and Human Tumor Cell Lines, Biochem, Biophys Res. Communications, Vol. 187, No. 1, pps. 164-170, 1992

Steve ROFFLER et al., "Potentiation of Radioimmunotherapy by Inhibition of Topoisomerase I, Cancer Res. 54, pps. 1276-85, 1994

Orlando SANTOS et al., "5-Iododeoxyuridine Increases the Efficacy of the Radioimmunotherapy of Human Tumors Growing in Nude Mice," Journal Nucl. Med. Vol. 33, No. 8, pps. 1530-34, 1992

Arne SKERRA et al., "Assembly of a Functional Immunoglobulin F<sub>v</sub> Fragment in Escherichia Coli, *Scient* Vol. 240, pps. 1038, 1988

Rhona STEIN et al., "Assessment of Combined Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Cancer, *Clin. Cancer, Res.* Vol. 5 pps. 3199s-3206s, 1999

Rhona STEIN et al., "Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma, Effectiveness of Dacarbazine, *Amer. Cancer Society*, 94, pps. 51-61.

Gary STILLWAGON Ph.D. et al., "Variable Low Dose Rate Irradiation (I-Anti-CEA) and Integrated Low Dose Chemotherapy in the Treatment of Nonresectable Primary Intrahepatic Cholangiocarcinoma, *Int., J. Radiation BNiol, Oncol., Phys.* 21, pps. 1601-05.

TANG et al., *Zhonghua Zhong Liu Za Zhi*, 12 pps. 2-5 (Article in Chinese and English Abstract enclosed).

TAYLOR-PAPADIMITRIOU et al., "Monoclonal Antibodies to Epithelium-Specific Components of the Human Milk Fat Globule Membrane: Production and Reaction with Cells in Culture, *Int. J. Cancer*, 28 pps. 17-21, 1981

Jorg TSCHMELITSCH et al., "Enhanced Antitumor Activity of Combination Radioimmunotherapy (131 I-Labeled Monoclonal Antibody A33) with Chemotherapy (Fluorouracil), *Cancer Res.* 57 pps. 2181-86, 1997

VERHOEYEN et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity, *Science* 239, pps. 1534-1536, 1988

Sally WARD et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli, *Nature* Vol. 341 pg. 544, 1989

BIH-RONG WEI et al., "The Combined Use of an Immunotoxin and a Radioimmunoconjugate to Treat Disseminated Human B-Cell Lymphoma in Immunodeficient Mice, *Clin. Cancer Res.* Vol. 6, pps. 631-42, 2000

Richard WILDER et al., "The Hypoxic Cytotoxin SR 4233 Increases the Effectiveness of Radioimmunotherapy in Mice with Human Non-Hodgkin's Lymphoma Xenografts, *Int. J. Radiat. Oncol. Biol. Phys.* Vol. 28 pps. 119-126, 1994

Greg WINTER & MILSTEIN, *Man-Made Antibodies*, *Nature* Vol. 349, pps.293-299, 1991

Jane WINTER, "Combining Yttrium 90-Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma, *Clin. Lymphoma* 5, pps. S22-s26, 2004

Jeffrey WONG et al., "A Phase I Trial of Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer, *Clin. Cancer Res.* Vol., 9, pps. 5842-52, 2003

Pier ZINZANI, "Traditional Treatment Approaches in B-Cell Non-Hodgkin's Lymphoma, *Leukemia & Lymphoma* 44, pps. S6-S14, 2003

HAJJAI, et al., "Initial Results of a Phase I Trial of Treatment of Medullary Thyroid Cancer with Radioimmunotherapy (RAIT) Combined Doxorubicin (Box) Proc. Amer. Soc. Clin. Oncol. 6a, 20, 2001

GRAVES et al., "Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively than either Monotherapy," Clin. Cancer Res. 9 pps., 3712-721, 2003

R. D. BLUMENTHAL et al., "Tumor-Specific Dose Scheduling of Bimodal Radioimmunotherapy and Chemotherapy, Anticancer Res. 23, pps. 4613-20, 2003

David GOLD et al., "Low-Dose Radioimmunotherapy (Y-Pam4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer, Clin. Cancer Res. 9, pps. 3929s-3937s, 2003

Oliver Press, Radioimmunotherapy for Non-Hodgkin's Lymphomas: A Historical perspective, Semin., Oncol. Vol. 30 pps., 10-21, 2003

CX ZHENG, "Influence of Combination of Low Dosage I-Labeled Anti-Carcinoembryonic Antigen Antibody C20 and 5-Fluorouracil on Tumor Growth of Colorectal Cancer Xenografts in Nude Mice, (English Abstract) Ai Zheng 22, pps. 354-57

H. ZOLA, Monoclonal Hybridoma Antibodies: Techniquet and Applications, JG R. Hurrell (CRC Press, 1982)


Monoclonal Hybridoma Antibodies: Techniquet and Applications, JG R. Hurrell (CRC Press, 1982)

Antibody Engineering, "A practical Approach", J. McCafferty et al., ed. (IRL Press 1996)

Accompanying this Information Disclosure Statement and form PTO-1449 is a copy of the document.

This submission is not an admission that the information disclosed in the documents is material to the patentability of the invention disclosed and/or claimed in the above-identified application.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jules E. Goldberg", written over a horizontal line.

Jules E. Goldberg Reg. No. 24,408  
Reed Smith LLP  
599 Lexington Avenue, 29<sup>th</sup> Floor  
New York, NY 10022

JEG:vh  
10/05/05  
Tel. (212) 521-5460  
Encl: Form PTO 1449 (9 pages)  
83 references





## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet | 1

of 19

Application Number

10/501.568

<b>Filing Date</b>
--------------------

April 5, 2005

First Named Inventor
----------------------

Gail Rowlinson-Busza
----------------------

**Art Unit**

1642

Examiner Name	
---------------	--

Fetterolf, Brandon J
----------------------

Attorney Docket Number

JG-EPC-5193/722489

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

## U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
	B	WO 01/74905	10-11-2001	Young, R.		
	C	WO 92/04380	03-19-1992	Verhoeyen, M.		
	D	EP 0 239 400	09-30-1987	Winter, G.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/501,568
		Filing Date	April 5, 2005
		First Named Inventor	Gail Rowlinson-Busza
		Art Unit	1642
		Examiner Name	Fetterolf, Brandon J
Sheet 2 of 9	Attorney Docket Number	JG-EPC-5193/722489	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	E	ALVAREZ, et al. A Phase I Study of Combined Modality 90 Yttrium-CC49 Intraperitoneal Radioimmunotherapy for Ovarian Cancer, 2002, Clin. Cancer Res. 8 pp2806-2811	
	F	BAO, Y M, et al., Radioimmunotherapy Combined with Chemo-Therapy and Immunotherapy for Nude Mice Bearing Human Hepatocellular Carcinoma, 1989 Zhongshai Hospital, Shanghai University of Medical Sciences, Shanghai, Zhonghua Zhong Liu Za Zhi, Chinese Journal, 11 pp 245-247, China (Article in Chinese and English abstract enclosed)	
	G	BEHR, et al. Improved Treatment of Medullary Thyroid Cancer in a Nude Mouse Model by Combined Radioimmunotherapy: Doxorubicin Potentiates the Therapeutic Efficacy of Radiolabeled Antibodies in a Radioresistant Tumor Type, 1997, Cancer Res. 57, pp 5309-5319	
	H	BETTER, et al. Escherichia coli Secretion of an Active Chimeric Antibody Fragment, Science Vol. 240, pp 1041-1043, 1988	
	I	ADIS R&D Profile, Abstract, Iodine-131 Tositumomab, Biodrugs, pg 17, 2003	
	J	BIRD, et al. Single-Chain Antigen -Binding Proteins, Science, pgs 242, 423, Oct. 1988	
	K	BLUMENTHAL Rosalyn et al., An In Vitro Model To Optimize Dose Scheduling Of Multimodal Radioimmunotherapy and Chemotherapy: Effects of p53 Expression, Int. J. Cancer pg 108, 293-300, 2004	
	L	BURKE, Patricia A. et al., Combined Modality Radioimmunotherapy, Promise Cancer, pgs 1320-1331, 2002	
	M	BURKE, Cilegitide Targeting of $\alpha$ v $\beta$ 3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts, Cancer Research 62, pgs. 4263-4272, 2002	
	N	Thomas M. Cardillo, et al., Combined Gemcitabine and Radioimmunotherapy for the Treatment of Pancreatic Cancer, Int. J. Cancer; pgs 386-392, 2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/501,568
Filing Date	April 5, 2005
First Named Inventor	Gail Rowlinson-Busza
Art Unit	1642
Examiner Name	Fetterolf, Brandon J
Attorney Docket Number	722489.00005

Sheet

3

of

9

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	O	CHALANDON et al., Combined Radioimmunotherapy and Chemotherapy of Human Colon Carcinoma Grafted in Nude Mice, Advantages and Limitations, Anticancer Research 12 pgs 1131-1140, 1992	
	P	CHEUNG, et al., N7: A Novel Multi-Modality Therapy of High Risk Neuroblastoma (NB) in Children Diagnosed Over 1 Year of Age, Medical and Pediatric Oncology 36:227-230, 2001	
	Q	K. CLARKE, et al., Therapeutic Efficacy of Anti-Lewis Humanized 3S193 Radioimmunotherapy in a Breast Cancer Model: Enhanced Activity When Combined with Taxol Chemotherapy, Clinical Cancer Research, 6 pgs 3621-3298, 2000	
	R	Gabriella D'ANDREA et al., Docetaxel and Paclitaxel in Breast Cancer Therapy: Present Status and Future Prospects, Seminars in Oncology Vol. 24 (4th Suppl. 13) pgs 27-44, 1997	
	S	Sally DENARDO et al., Synergistic Therapy of Breast Cancer with Y-90-Chimeric L6 and Paclitaxel in the Xenografted Mouse Model: Development of a Clinical Protocol, Anticancer Res. 18 pgs 4011-18, 1998	
	T	Sally DENARDO et al., Synergistic of Taxol and Radioimmunotherapy with Yttrium-90-Labeled Chimeric L6 Antibody: Efficacy and Toxicity in Breast Cancer Xenografts, Proc. Natl. Acad. Sci. USA 94 pgs 4000-4, 1997	
	U	B. DESRUES et al., Monoclonal Antibody Po66 Uptake By Human Lung Tumours Implanted in Nude Mice: Effect of Co-Administration with Doxorubicin, Br. J. Cancer 72 pgs 1076-82, 1995	
	V	B. DESRUES et al., Treatment of Human Lung Carcinoma Xenografts with a Combination of 131I-Labelled Monoclonal Antibody Po66 and Doxorubicin, Cancer Immunol Immunother 43 pgs 269-74, 1996	
	W	FABRE et al., Docetaxel Antineoplastic Microtubule Stabilizer, Drugs of the Future, 20, pgs 464-471, 1995	
	X	Sandra GENDLER et al., A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas is Made Up of Tandem Repeats, Journal of Biol. Chem, 263, pgs 12820-23, 1986	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/501,568
				Filing Date	April 5, 2005
				First Named Inventor	Gail Rowlinson-Busza
				Art Unit	1642
				Examiner Name	Fetterolf, Brandon J
Sheet	4	of	9	Attorney Docket Number	JG-EPC-5193/722489

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	Y	Dr. S. GILLIES, Antibody Cytokine Concept Optimising the Therapeutic Potential of Antibody-Cytokine Fusion Proteins, London, June 27 and 28, 2001, pp. 1-36		
	Z	David V. GOLD, et al. Combined Yttrium-Dota-Labeled PAM4 Antibody Radioimmunotherapy and Gemcitabine Radiosensitization for the Treatment of a Human Pancreatic Cancer Xenograft, Int. J. Cancer 109 pgs, 618-26, 2004		
	AA	David GOLDENBERG, The Role of Radiolabeled Antibodies in the Treatment of non-Hodgkin's Lymphoma: the Coming of Age of Radioimmunotherapy, Critical Reviews in Oncology/Hematology, 39, pgs 195-201, 2001		
	AB	Ajay GOPAL, et al. High-Dose Chemo-Radioimmunotherapy with Autologous Stem Cell Support for Relapsed Mantel Cell Lymphoma, Blood Vol. 99 pgs 3158-62, 2002		
	AC	M. HERNANDEZ, et al., Radiobiology og Radioimmunotherapy: Targeting CD20 B-Cell Antigen in non-Hodgkin's Lymphoma, Int. J. Radiation Oncology Biol. Phys. Vol 59, pgs 1274-87, 2004		
	AD	James S. HUSTON, et al., Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv analogue Produced in Escherichia Coli, Proc. Natl. Acad. Sci. USA pgs 5879-83, 1988		
	AE	Timothy JOHNSON, et al., Synergistic Cytotoxicity of Iodine-131-Anti-CD20 Monoclonal Antibodies and Chemotherapy for Treatment of B-Cell Lymphomas, Int. J. Cancer, 85, 104-12, 2000		
	AF	Peter JONES, et al. Replacing the Complementarity-determining Regions in a Human Antibody with Those from a Mouse, Nature, Vol. 321, pgs 522-25, 1986		
	AG	Malik JUWEID M.D., Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice, J. Nucl. Med. 43, pgs 1507-29, 2002		
	AH	Seigo KINUYA, et al. Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with Thalidomide in Human Cancer Xenografts, Int. J. Cancer 43, pgs. 1084-89, 2002		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/501,568
Filing Date	April 5, 2005
First Named Inventor	Rowlinson-Busza, Gail
Art Unit	1642
Examiner Name	Fetterolf, Brandon J
Attorney Docket Number	JG-EPC-5193/722489

Sheet

5

of

9

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AJ	Seigo KINUYA et al., Efficacy, Toxicity and Mode of Interaction of Combination Radioimmunotherapy with 5-fluorouracil in Colon Cancer Xenografts, J. Cancer Res Clin Oncol 125 pgs 630-36, 1999	
	AK	Seigo KINUYA et al., Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model, Jpn. J. Cancer Res. 91, pgs 573-78, 2000	
	AL	Seigo KINUYA et al., Anti-Angiogenic Therapy and Radioimmunotherapy In Colon Cancer Xenografts, Eur J. Nucl Med., Vol. 28, No. 9, 28 pgs 1306-12, 2001	
	AM	Seigo KINUYA et al., Improved Response of Colon Cancer Xenografts to Radioimmunotherapy with Pentoxifylline Treatment, Eur J. Nucl. Med. Vol. 28, pgs. 750-755, 2001	
	AN	Seigo KINUYA et al., Improved Survival of Mice Bearing Liver Metastases of Colon Cancer Cells Treated with a Combination of Radioimmunotherapy and Antiangiogenic Therapy, Eur J. Nucl. Med. Vol. 31, pgs 981-85, 2004	
	AO	Francoise Kraeber-Bodere et al., Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft, Mol. Cancer Ther. Vol. 1 pgs 267-74, 2002	
	AP	Xiao Li et al., Benefits of Combined Radioimmunotherapy and anti-angiogenic therapy in a Liver Metastasis Model of Human Colon Cancer Cells, Eur. J. Nucl. Med. Mol. Imaging Vol. 29 pgs 1669-1674, 2002	
	AQ	Anthony Maraveyas, et al., Radiolabeled Antibody Combined with External Radithery for the Treatment of Head and Neck Cancer: Reconstruction of Theoretical Phantom of the Larynx for Radiation Dose Calculation to Local Tissues, Cancer Research 55, pgs. 1020-1027, 1995	
	AR	Ruby Meredith, et al., Intraperitoneal Radioimmunotherapy of Ovarian Cancer: A Phase I Study, Cancer Biotherapy, Radiopharm Vol. 16, pgs. 305-15, 2001	
	AS	Ivana Micallef, Ongoing Trials with Yttrium 90-Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma, Clin Lymphoma 5, pgs. S27-S32, 2004	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/501,568
Filing Date	April 5, 2005
First Named Inventor	Rowlinson-Busza, Gail
Art Unit	1642
Examiner Name	Fetterolf, Brandon J
Attorney Docket Number	JG-EPC-5193/722489

Sheet

6

of

9

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AT	Bruce NG, et al., Radiosensitization of Tumor-Targeted Radioimmunotherapy with Prolonged Toptecan Infusion in Human Breast Cancer Xenografts, Cancer Research 61, pgs 2996-3001, 2001	
	AU	Robert O'DONNELL, et al., Combined Modality Radioimmunotherapy with Taxol and Y-LYM-1 for Raji Lymphoma Xenografts, Cancer Biother. Radiopharm Vol. 13, pgs. 351-61, 1998	
	AV	Robert O'DONNELL et al., Combined Modality Radioimmunotherapy for Human Prostate Cancer Xenografts with Taxanes and Yttrium-DOTA-Peptide-ChL6, Prostate 50:27, pgs 27-37, 2002	
	AW	R. BARBARA PEDLEY, et al. Enhancement of Radioimmunotherapy by Drugs Modifying Tumour Blood Flow in a Colonic Xenograft Model, Int. J. Cancer 57 pgs. 830-35, 1994	
	AX	R. BARBARA PEDLEY, et al. Ablation of Colorectal Xenografts with Combined Radioimmunotherapy and Tumor Blood Flow-Modifying Agents, Cancer Res.56, pgs 3293-3300, 1996	
	AY	R. BARBARA PEDLEY, et al. Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate, Cancer Res. 61, pgs. 4716-4722, 2001	
	AZ	R. BARBARA PEDLEY, et al. Synergy Between Vascular Targeting Agents and Antibody-Directed Therapy, Int. J. Radiation Oncology Biol. Phys. 54 pgs. 1524-31, 2002	
	BA	Oliver PRESS, et al., A Phase I/II Trial of Iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and Autologous Stem Cell Transplantation for Relapsed B-Cell Lymphomas, Am. Soc. Hematol., Blood, pgs Vol. 96, No. 9, 221-240, 2000	
	BB	Oliver PRESS, et al, Immunotherapy of Non-Hodgkin's Lymphomas, Hematology, pgs. 221-240, 2001	
	BC	PRESS, et al, A Phase 2 Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I 131 Tositumomab for Previously Untreated Follicular non-Hodgkin Lymphoma: Southwest Oncology Group Protocol S9911, Blood 102, 2003	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

9

**Complete if Known**

Application Number	10/501,568
Filing Date	April 5, 2005
First Named Inventor	Rowlinson-Busza, Gail
Art Unit	1642
Examiner Name	Fetterolf, Brandon J
Attorney Docket Number	JG-EPC-5193/722489

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BD	M. REISER, et al, Current Treatment of Follicular non-Hodgkin's Lymphoma, Eur. J. Cancer 38 pgs. 1167-1172, 2002	
	BE	L. REICHMANN, et al, Reshaping Human Antibodies for Therapy, Nature 322, pgs. 323-27, 1988	
	BF	Jean Francois RIOU, et al, Effects of Taxotere on Murine and Human Tumor Cell Lines, Biochem. Biophys Res. Communications, Vol. 187, No. 1, pgs. 164-170, 1992	
	BG	Steve ROFFLER, et al., Potentiation of Radioimmunotherapy by Inhibition of Topoisomerase I, Cancer Res. 54, pgs. 1276-85, 1994	
	BH	Orlando SANTOS, et al. 5-Iododeoxyuridine Increases the Efficacy of the Radioimmunotherapy of Human Tumors Growing in Nude Mice, Journal Nucl. Med. Vol. 33, No. 8, pgs. 1530-34, 1992	
	BI	Arne SKERRA, et al., Assembly of a Functional Immunoglobulin Fv Fragment in Escherichia Coli, Science Vol. 240, pg. 1038, 1988	
	BJ	Rhona STEIN, et al. Assessment of Combined Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Cancer, Clin. Cancer. Res. Vol. 5 pgs 3199s-3206s, 1999	
	BK	Rhona STEIN, et al. Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma, Effectiveness of Dacarbazine, Amer. Cancer Society, 94, pgs. 51-61	
	BL	Gary Stillwagon Ph.D. et al. Variable Low Dose Rate Irradiation (I-ANTI-CEA) and Integrated Low Dose Chemotherapy in the Treatment of Nonresectable Primary Intrahepatic Cholangiocarcinoma, Int. J. Radiation BNiol. Oncol. Phys. 21, pgs 1601-05	
	BM	Tang, et al. Zhonghua Zhong Liu Za Zhi 12 pgs 2-5 (Article in Chinese and English abstract enclosed)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

8

of

9

**Complete if Known**

Application Number

10/501,568

Filing Date

April 5, 2005

First Named Inventor

Rowlinson-Busza, Gail

Art Unit

1642

Examiner Name

Fetterolf, Brandon J

Attorney Docket Number

JG-EPC-5193/722489.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BN	Taylor-Papadimitriou et al., Monoclonal Antibodies to Epithelium-Specific Components of the Human Milk Fat Globule Membrane: Production and Reaction with Cells in Culture, Int. J. Cancer, 28, pgs 17-21, 1981	
	BO	Jorg Tschmelitsch et al. Enhanced Antitumor Activity of Combination Radioimmunotherapy ( 131 I-Labeled Monoclonal Antibody A33) with Chemotherapy (Fluorouracil), Cancer Res. 57 pgs 2181-86, 1997	
	BP	Verhoeven et al. Reshaping Human Antibodies: Grafting an Antilysozyme Activity, Science 239, pgs 1534-1536, 1988	
	BQ	Sally Ward et al., Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli, Nature Vol. 341 pg. 544, 1989	
	BR	Bih-Rong Wei et al., The Combined Use of an Immunotoxin and a Radioimmunoconjugate to Treat Disseminated Human B-Cell Lymphoma in Immunodeficient Mice, Clin. Cancer Res. Vol. 6 pgs 631-42, 2000	
	BS	Richard Wilder et al., The Hypoxic Cytotoxin SR 4233 Increases the Effectiveness of Radioimmunotherapy in Mice with Human Non-Hodgkin's Lymphoma Xenografts, Int. J. Radiat. Oncol. Biol. Phys. Vol. 28 pgs. 119-126, 1994	
	BT	Greg Winter & Milstein, Man-Made Antibodies, Nature, Vol. 349, pps. 293-299, 1991	
	BU	Jane Winter, Combining Yttrium 90-Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma, Clin. Lymphoma 5, pgs S22-S26, 2004	
	BV	Jeffrey Wong; et al, A Phase I Trial of Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer, Clin. Cancer Res. Vol. 9, pgs. 5842-52, 2003	
	BW	Pier Zinzani, Traditional Treatment Approaches in B-Cell Non-Hodgkin's Lymphoma, Leukemia & Lymphoma 44, pgs. S6-S14, 2003	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/501,568
				Filing Date	April 5, 2005
				First Named Inventor	Gail Rowlinson-Busza
				Art Unit	1642
				Examiner Name	Fetterolf, Brandon J
Sheet	9	of	9	Attorney Docket Number	JG-EPC-5193/722489

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BX	Hajjai, et al. Initial Results of a Phase I Trial of Treatment of Medullary Thyroid Cancer with Radioimmunotherapy (RAIT) Combined Doxorubicin (Box) Proc. Amer. Soc. Clin. Oncol. 6a, 20, 2001	
	BY	Graves, et al. Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy, Clin. Cancer Res. 9 pgs. 3712-721, 2003	
	BZ	R. D. Blumenthal, et al., Tumor-Specific Dose Scheduling of Bimodal Radioimmunotherapy and Chemotherapy, Anticancer Res 23, pgs. 4613-20, 2003	
	CA	David Gold, et al. Low-Dose Radioimmunotherapy (Y-Pam4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer, Clin. Cancer Res. 9, pgs 3929s-3937s, 2003	
	CB	Oliver Press, Radioimmunotherapy for Non-Hodgkin's Lymphomas: A Historical Perspective, Semin. Oncol. Vol. 30, pgs. 10-21, 2003	
	CC	CX Zheng, Influence of Combination of Low Dosage I-Labeled Anti-Carcinoembryonic Antigen Antibody C20 and 5-Fluorouracil on Tumor Growth of Colorectal Cancer Xenografts in Nude Mice, (English Abstract) Ai Zheng 22, pgs. 354-57	
	CD	H. ZOLA, Monoclonal Antibodies: A Manual of Techniques, (CRC Press, 1988)	
	CE	Monoclonal Hybridoma Antibodies: Techniquet and Applications, JG R Hurrell (CRC Press, 1982)	
	CF	Antibody Engineering, A Practical Approach, J. McCafferty et al., ed. (IRL Press, 1996)	
	CG		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.